NCT07000292View on ClinicalTrials.gov

MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

May 20, 2026

Study Completion Date

February 20, 2027

Conditions
Lupus Nephritis (LN)ANCA-Associated Glomerulonephritis
Interventions
DRUG

Injection of MSC303

Dose Group 1: D1, D8, D15, and D36 were respectively given 1, 5, 15, and 15 mg of MSC303 for injection; The second dose group: D1, D8, D15 and D36 were respectively given for injection MSC303 1, 5, 20, 20 mg.

Trial Locations (1)

200003

Shanghai Changzheng Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Changzheng Hospital

OTHER